DCM
LPCN icon

DAFNA Capital Management’s Lipocine LPCN Stock Holding History

DAFNA Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,631
Closed -$972K – 99
2016
Q1 		$972K Buy
5,631
+2,690
+91% +$459K 0.84% 38
2015
Q4 		$647K Buy
2,941
+294
+11% +$61.7K 0.58% 45
2015
Q3 		$532K Sell
2,647
-2,353
-47% -$544K 0.53% 52
2015
Q2 		$729K Buy
+5,000
New +$621K 0.62% 45

Other funds holding LPCN

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DAFNA Capital Management's LPCN Position: Q2 2016 in Review

DAFNA Capital Management sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 5,631 shares — an estimated $972K sold.

DAFNA Capital Management first reported a position in LPCN in Q2 2015 and held it in 4 quarters. The position peaked at $972K in Q1 2016. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

  • DAFNA Capital Management reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 5,631 Lipocine shares in Q2 2016, an estimated $972K.
  • DAFNA Capital Management first reported a position in Lipocine in Q2 2015 and held it in 4 quarters.
  • DAFNA Capital Management's Lipocine position peaked at $972K in Q1 2016.
  • 54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on DAFNA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.